Predicting survival in follicular lymphoma using tissue microarrays
- PMID: 17634622
- DOI: 10.1007/978-1-59745-390-5_16
Predicting survival in follicular lymphoma using tissue microarrays
Abstract
A tissue microarray (TMA) containing diagnostic biopsies was used to develop predictors of outcome in a group of 105 patients having advanced-stage follicular lymphoma (FL). The patients were staged and uniformly treated, and the usable cases had been randomly divided into a subgroup of 50 patients with outcomes identified, and a reserved subgroup of 43 patients whose outcomes were masked for blind testing of the predictors. Using training-input data from some patients with known outcomes, parallel cascade identification developed two predictors of overall survival based on a number of biomarkers. Both predictors had statistically significant performance over the remaining patients with known outcomes. The first predictor had been identified with model architectural settings and encoding scheme chosen, for the particular training input used, to enhance classification accuracy over remaining patients in the known subgroup. The second predictor was obtained without changing the settings and encoding scheme, but from an entirely different training input corresponding to novel cases from the TMA. Not surprisingly, the first predictor showed much higher accuracy over the known subgroup, but when tested over the reserved subgroup of 43 patients, averaged about 58% correct and did not reach statistical significance. The other predictor performed very similarly over the known and the reserved subgroups, with prediction on the reserved subgroup highly significant at p = 0.0056 in Kaplan-Meier survival analysis. We conclude that a predictor based on a number of biomarkers obtainable at diagnosis has the potential to improve prediction of overall survival in FL.
Similar articles
-
Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.J Clin Oncol. 2007 Aug 1;25(22):3330-6. doi: 10.1200/JCO.2006.10.5833. J Clin Oncol. 2007. PMID: 17664481
-
Signal transducers and activators of transcription 5a-dependent cross-talk between follicular lymphoma cells and tumor microenvironment characterizes a group of patients with improved outcome after R-CHOP.Clin Cancer Res. 2010 May 1;16(9):2615-23. doi: 10.1158/1078-0432.CCR-09-3269. Epub 2010 Apr 13. Clin Cancer Res. 2010. PMID: 20388848
-
Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP.Br J Haematol. 2006 Oct;135(1):33-42. doi: 10.1111/j.1365-2141.2006.06255.x. Epub 2006 Aug 22. Br J Haematol. 2006. PMID: 16925574
-
[Follicular lymphoma].Orv Hetil. 2003 Nov 16;144(46):2253-61. Orv Hetil. 2003. PMID: 14702920 Review. Hungarian.
-
Prognostic biomarkers in diffuse large B-cell lymphoma.J Clin Oncol. 2006 Feb 20;24(6):995-1007. doi: 10.1200/JCO.2005.02.4786. Epub 2006 Jan 17. J Clin Oncol. 2006. PMID: 16418498 Review.
Cited by
-
From drug discovery to biomarker-driven clinical trials in lymphoma.Nat Rev Clin Oncol. 2012 Nov;9(11):643-53. doi: 10.1038/nrclinonc.2012.156. Epub 2012 Sep 11. Nat Rev Clin Oncol. 2012. PMID: 22965151 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources